slobo/iStock Unreleased via Getty Images By Khaveen Jey, CFA, FMVA, Portfolio Manager @ Khaveen Investments & Nicholas Tan, Investment Research Analyst @ Khaveen Investments. In this analysis, we initiate our coverage of Costco ( COST ), a dominant global membership-only retailer that provides its members with quality products at low prices. Costco's revenue has been growing with an average growth...
slobo/iStock Unreleased via Getty Images By Khaveen Jey, CFA, FMVA, Portfolio Manager @ Khaveen Investments & Nicholas Tan, Investment Research Analyst @ Khaveen Investments. In this analysis, we initiate our coverage of Costco ( COST ), a dominant global membership-only retailer that provides its members with quality products at low prices. Costco's revenue has been growing with an average growth rate of 9.86% over the last 10 years. The company's net margins have also consistently improved, rising from 1.98% in 2016 to 2.96% in TTM. We thus analyze whether the company could continue to maintain its stable and profitable growth. We first evaluate whether it could retain its competitive positioning by examining its market share, its competitiveness, and the cost strategies underpinning its competitive positioning. We then examine whether it can continue growing by analyzing its revenue growth drivers, such as average revenue per member ('ARPM'), members per store, and store numbers. We analyzed ARPM as it would help us understand each consumer's spending amount in store and whether it has been rising, while we examined its members per store because more members per store would directly affect how much sales each store makes. We evaluated store numbers, as more stores would indicate more locations to generate revenue. We further examine whether it could maintain its profit margins by evaluating its historical margins breakdown and its membership net margins. We analyze its membership net margins, as their high margins are used to offset low product prices. Robust Market Share and Competitive Advantage In our first section, we analyze whether the company could maintain its competitive position, as a weakening competitive position could hamper its growth outlook. We thus compile the top US retailers' retail-related revenue within the Consumer Staples Merchandise Retail and Food Retail sub-industry from GICS. We also included Amazon ( AMZN ), as Amazon also operates as ...
Renaissance Technologies trimmed its Alphabet position in Q4 of 2025 by a big margin. The quantitative trading giant, founded by the late mathematician Jim Simons, slashed its Alphabet (GOOGL) stock stake by 88.6% in the fourth quarter of 2025, according to Tikr.com, selling down to just 296,470 ...
Renaissance Technologies trimmed its Alphabet position in Q4 of 2025 by a big margin. The quantitative trading giant, founded by the late mathematician Jim Simons, slashed its Alphabet (GOOGL) stock stake by 88.6% in the fourth quarter of 2025, according to Tikr.com, selling down to just 296,470 ...
On February 17, 2026, Baker Bros. Advisors disclosed a purchase of 455,208 shares of GRAIL (NASDAQ:GRAL) , an estimated $39.33 million trade based on quarterly average pricing. According to a recent SEC filing dated February 17, 2026, Baker Bros. Advisors increased its position in GRAIL by 455,208 shares. The estimated transaction value, based on the average unadjusted closing price during the fou...
On February 17, 2026, Baker Bros. Advisors disclosed a purchase of 455,208 shares of GRAIL (NASDAQ:GRAL) , an estimated $39.33 million trade based on quarterly average pricing. According to a recent SEC filing dated February 17, 2026, Baker Bros. Advisors increased its position in GRAIL by 455,208 shares. The estimated transaction value, based on the average unadjusted closing price during the fourth quarter of 2025, was $39.33 million. The quarter-end value of the position rose by $82.09 million, reflecting the combined impact of additional shares and changes in the stock price. The position represents roughly 1% of assets. GRAIL is a biotechnology company specializing in advanced diagnostics for early cancer detection. The company leverages proprietary technology to address significant unmet needs in oncology screening and diagnosis. With a focus on innovation and clinical utility, GRAIL aims to improve patient outcomes and establish a leadership position in the medical diagnostics market. Continue reading
The second-gen trackers look similar to the originals but come with a few welcome upgrades. | Photo by Amelia Holowaty Krales / The Verge Less than a month after making their debut, Apple’s second-gen AirTags are already receiving their first discount. Right now, Costco members can buy five location trackers for $99.99 ($29 off) either online or in-store, bringing the price of each tracker down to...
The second-gen trackers look similar to the originals but come with a few welcome upgrades. | Photo by Amelia Holowaty Krales / The Verge Less than a month after making their debut, Apple’s second-gen AirTags are already receiving their first discount. Right now, Costco members can buy five location trackers for $99.99 ($29 off) either online or in-store, bringing the price of each tracker down to about $20 a pop. If you don’t already belong to Costco, you can still take advantage of the discount if you’re willing to pay a $5 surcharge or sign up for an annual membership, which currently starts at $65 a year. Apple AirTag (second-gen) Where to Buy: $145 $99.99 at Costco (five-pack) Apple’s original AirTag has been our favorite tracker for iPhone users for years, and the newest version builds upon that excellence with some welcome improvements. What has always set the AirTag apart is Apple’s ultra wideband chip, which allows for an impressive level of precision that competing products like the Tile Pro can’t match. The company’s new, upgraded chip still guides you straight to misplaced items with on-screen arrows, vibrations, and sounds, but now from up to 50 percent farther away. The extended range also makes tracking items in multi-story homes much more reliable, and even makes it faster to connect the AirTag to your phone. The built-in speaker is also 50 percent louder, making it easier to locate the item trackers when they’re hidden from view. The new model also keeps everything we loved in the original AirTag. It still uses a user-replaceable battery, so you don’t need to replace it when it inevitably dies after a year or so. You also get the same IP67 water and dust resistance, extended Bluetooth range, and handy software features that let you share your tracker with up to five people or temporarily share its location with airlines, such as United , Delta , and American Airlines . Read our full AirTag (second-gen) review .
David Petrus Ibars/E+ via Getty Images The Roundhill GLP-1 & Weight Loss ETF ( OZEM ) came into focus on Monday after Novo Nordisk ( NVO ) shares tumbled as the firm's next-generation obesity drug CagriSema delivered less weight loss than Eli Lilly’s ( LLY ) competing treatment in a phase 3 trial. The results raised new concerns about its sales potential. Patients taking a standard dose of CagriSe...
David Petrus Ibars/E+ via Getty Images The Roundhill GLP-1 & Weight Loss ETF ( OZEM ) came into focus on Monday after Novo Nordisk ( NVO ) shares tumbled as the firm's next-generation obesity drug CagriSema delivered less weight loss than Eli Lilly’s ( LLY ) competing treatment in a phase 3 trial. The results raised new concerns about its sales potential. Patients taking a standard dose of CagriSema lost 20.2% of their body weight after 84 weeks, compared with 23.6% for Lilly’s tirzepatide. Here are the top holdings of OZEM and their quant ratings: Novo Nordisk ( NVO ): 2.88, Hold Eli Lilly and Co ( LLY ): 3.45, Hold Structure Therapeutics ( GPCR ): 3.46, Hold Roche ( RHHBY ): 3.21, Hold Pfizer ( PFE ): 3.33, Hold Amgen ( AMGN ): 3.34, Hold More on Roundhill GLP-1 & Weight Loss ETF OZEM Vs. THNR: Which Is The Better ETF In The GLP-1 And Weight Loss Space? OZEM stock: What the Ratings say Seeking Alpha’s Quant Rating on Roundhill GLP-1 & Weight Loss ETF Dividend scorecard for Roundhill GLP-1 & Weight Loss ETF
"Go F**k Yourself": Immigrant-Owned Maryland Crab Shack Goes Viral After Slamming HuffPo Over Anti-USA Olympic Story It was a historic moment for Team USA Hockey as Jack Hughes scored the game-winning goal in a dramatic overtime finish, defeating Canada for the gold medal in Milan. The last time USA won Olympic gold in hockey was during the "Miracle on Ice" at the 1980 Winter Olympics. Now, the ce...
"Go F**k Yourself": Immigrant-Owned Maryland Crab Shack Goes Viral After Slamming HuffPo Over Anti-USA Olympic Story It was a historic moment for Team USA Hockey as Jack Hughes scored the game-winning goal in a dramatic overtime finish, defeating Canada for the gold medal in Milan. The last time USA won Olympic gold in hockey was during the "Miracle on Ice" at the 1980 Winter Olympics. Now, the celebration heads to Washington, with President Trump inviting Hughes and his teammates to the White House. The thrilling 2-1 victory ended Team USA's nearly five-decade Olympic gold drought and marked one of the biggest moments in the US hockey program. "I'll tell you what. I just told my people two minutes ago, I didn't know they'd be calling. I said we're giving the State of the Union speech on Tuesday night," President Trump told the players. "I can send a military plane or something, but if you would like to, it's the coolest night. It's the biggest speech …" One player told Trump, "Sir, we're in." 🚨 EPIC! Kash Patel put PRESIDENT TRUMP on the phone in Team USA’s locker room so that 47 could PERSONALLY congratulate them “Congratulations! That was an UNBELIEVABLE game! We love you guys!” “You’re going to be proud of that game for FIFTY YEARS!” “I can send a MILITARY… pic.twitter.com/GGCUOadySq — Nick Sortor (@nicksortor) February 23, 2026 The New Jersey Devils star became the face of Team USA Hockey and ignited a sense of pride in being American, while the left-leaning outlet HuffPost wrote, "If waving the American flag or chanting 'USA!' turns you off right now, you're not alone." Responding to the HuffPost post on X, a Maryland restaurant named Jimmy's Famous Seafood went absolutely viral for calling out the publication, replying, "Go f**k yourself." Go fuck yourself — Jimmy’s Famous Seafood (@JimmysSeafood) February 22, 2026 Jimmy's Famous Seafood's response on X went viral, with more than 9 million views. The restaurant, which also sells crab cakes online, saw such an...
Dragon Claws/iStock via Getty Images It is normal for volatile reactions to happen at key levels (or a short time after), like previous peaks or upward-sloping resistance lines. Often, these reactions (or consolidations) can have a similar shape or structure. This was recently the case for this gold chart illustrated to project gold’s future movements: Here is a comparison of the two patterns at t...
Dragon Claws/iStock via Getty Images It is normal for volatile reactions to happen at key levels (or a short time after), like previous peaks or upward-sloping resistance lines. Often, these reactions (or consolidations) can have a similar shape or structure. This was recently the case for this gold chart illustrated to project gold’s future movements: Here is a comparison of the two patterns at the breakout lines from a close-up view: I have marked the two fractals to show how they are similar. If the comparison is justified, then we could see a strong move higher over the coming months. The two patterns occurred at similar upward-sloping resistance lines and were following a similar structure. The breakouts at both upward-sloping lines were important signals that price would go significantly higher should it successfully break higher. It eventually did break higher, and after that, gold rose from about $3300 to the recent $5597. The silver chart is now potentially facing a similar situation. Here is a silver chart that I showed previously: It shows two important upward-sloping resistance lines. The blue line is the bottom of the important channel described here . A break into that channel suggests that silver is roughly in a position similar to 2004. The red line is an important trigger for a bullish pattern highlighted in a previous post. This pattern already reached its target shortly after the reaction/consolidation at the red line. There is now a similar pattern at the blue line (as can be seen on this chart): If these patterns continue in a similar manner, then we could see silver move past $200 over the coming months. Original Post Editor's Note: The summary bullets for this article were chosen by Seeking Alpha editors.
Prediction markets have driven a lot of attention. These platforms allow prospective investors and speculators to trade on the outcomes of real-world events ranging from sporting events to elections to even weather-related events. One of the more prominent prediction market has become Kalshi. Although some analysts worry it blurs the line between investing and gambling , it has become highly succe...
Prediction markets have driven a lot of attention. These platforms allow prospective investors and speculators to trade on the outcomes of real-world events ranging from sporting events to elections to even weather-related events. One of the more prominent prediction market has become Kalshi. Although some analysts worry it blurs the line between investing and gambling , it has become highly successful. With that, its performance has naturally led to questions as to whether the company will launch an IPO and begin trading on the stock market in 2026. Continue reading
Novo Nordisk A/S ’s next-generation weight-loss drug CagriSema isn’t even on the market yet, but the company’s chief executive officer is already batting back suggestions that the drug is obsolete following the release of disappointing trial results on Monday. Among investors, news of CagriSema’s poor showing against Eli Lilly & Co.’s Zepbound sparked calls for a radical shift. Novo shares plummet...
Novo Nordisk A/S ’s next-generation weight-loss drug CagriSema isn’t even on the market yet, but the company’s chief executive officer is already batting back suggestions that the drug is obsolete following the release of disappointing trial results on Monday. Among investors, news of CagriSema’s poor showing against Eli Lilly & Co.’s Zepbound sparked calls for a radical shift. Novo shares plummeted 16.5% in the latest dramatic fall for a stock that is down about 61% in the past year. Some investors are now leaning on Novo CEO Mike Doustdar to diversify away from diabetes and obesity, the twin fields that have defined the Danish drugmaker for the past 30 years. “They just need another leg,” said Markus Manns, portfolio manager at Frankfurt-based Union Investment and a Novo investor. “Obesity and diabetes — it’s too risky to bet the entire company on these two franchises.” Watch More: Novo New Obesity Shot Falls Short of Lilly Rival Expanding its repertoire would reduce Novo’s risk as its blockbuster drugs Ozempic and Wegovy brace for generic competition in the US market early next decade, according to analysts and investors. Still, such a pivot would be a significant move for Novo, which established the modern obesity market and has been a leader in diabetes medication since its founding some 120 years ago. “We want to retain and sustain and grow our leadership in diabetes and obesity and be the best in world within those two areas,” Doustdar said earlier this month at a presentation of the company’s full-year results. Although Novo’s Wegovy was first to market among the current generation of powerful weight-loss drugs, it has struggled to keep up with Zepbound. By the time that drug beat Wegovy in a head-to-head obesity study last year, Novo had already pinned its hopes on CagriSema as the next-generation medicine that would cement its dominance. But the study published today showed that CagriSema’s 20.2% weight-loss for people treated with a standard dose failed t...
Ontario Municipal Employees Retirement System returned 6% last year after gains from stock holdings and private credit more than offset private equity losses and a weak dollar. That brings its net assets to C$145.2 billion ($106 billion) last year, up from C$138.2 billion in 2024, the pension said in a statement Monday. “Volatile currency markets create challenges for many investors who invest abr...
Ontario Municipal Employees Retirement System returned 6% last year after gains from stock holdings and private credit more than offset private equity losses and a weak dollar. That brings its net assets to C$145.2 billion ($106 billion) last year, up from C$138.2 billion in 2024, the pension said in a statement Monday. “Volatile currency markets create challenges for many investors who invest abroad,” Chief Executive Officer Blake Hutcheson said in the statement, adding that decisions to hedge currencies helped “limit the foreign exchange impact on our results to negative 1.3%, driven mainly by the strong decline in the value of the US dollar.” Public equity holdings gained 12.3% last year, while private credit and infrastructure delivered 8.3% and 6% returns, respectively. Investments in private equity lost 2.5%, compared with a 9.5% gain in 2024. The pension plan has revamped its private equity group over the past two years, including hiring a new global head, halting direct buyouts in Europe and cutting a team focused on the asset class in Asia. Read More: Canada’s Stewards of $1.2 Trillion Money Pot Revamp PE Model Earlier this month the private equity arm agreed to sell specialty care management company Paradigm to Patient Square Capital , and in December CBI Health , one of Omers’ longstanding portfolio companies, agreed to sell its home-care business to Extendicare Inc. in December. Omers said that it is “well-positioned” to invest in Canada and that it’s seeking “near-term opportunities in Canada that will support both our objectives and the country’s growth.”
Viktor Orbán’s government blocks fresh economic measures against Russia on eve of war’s fourth anniversary Europe live – latest updates European leaders have accused Hungary of sabotaging support for Ukraine on the eve of the fourth anniversary of Vladimir Putin’s full-scale invasion, after a defiant Budapest blocked fresh economic measures against Moscow. Germany, France and other EU states faile...
Viktor Orbán’s government blocks fresh economic measures against Russia on eve of war’s fourth anniversary Europe live – latest updates European leaders have accused Hungary of sabotaging support for Ukraine on the eve of the fourth anniversary of Vladimir Putin’s full-scale invasion, after a defiant Budapest blocked fresh economic measures against Moscow. Germany, France and other EU states failed to persuade Viktor Orbán’s government on Monday to approve the latest EU sanctions package and a loan meant to help Kyiv meet its military and financial needs. Poland’s prime minister, Donald Tusk, described Hungary’s actions as “political sabotage”. Continue reading...
(PRO Views are exclusive to PRO subscribers, giving them insight on the news of the day direct from a real investing pro. See the full discussion above.) Highly awaited quarterly results from Nvidia and two key software stocks will test important levels in the market this week, Jay Woods says. Woods, chief market strategist at Freedom Capital Markets, is looking to see Nvidia stock move steadily h...
(PRO Views are exclusive to PRO subscribers, giving them insight on the news of the day direct from a real investing pro. See the full discussion above.) Highly awaited quarterly results from Nvidia and two key software stocks will test important levels in the market this week, Jay Woods says. Woods, chief market strategist at Freedom Capital Markets, is looking to see Nvidia stock move steadily higher on the back of its fiscal fourth-quarter earnings due after market close Wednesday. That's because of some choppy post-earnings moves in tech recently, Woods said, noting both Meta and Palantir shares declined even after the company's had great results. Even more important to consider is the effect of Nvidia's report on the S & P 500 , given its 7% stake in the broader market, Woods said. The S & P 500's repeated tests of the 7,000 level are putting a focus to the index's 100-day moving average at 6,822, he said. "Watch how [Nvidia] closes on Thursday. ... We want to see it open strong, stay strong. If not, if it pulls back, watch the 200-day moving average, this $173 area in Nvidia," Woods said. "If it breaks it, that would be a tell for this entire market. We could get a big flush out to 6,600 in the S & P 500 and Nvidia could go back to $150 over the next several months. So, very critical to watch the price action in Nvidia." Nvidia shares are up 2% year to date. The stock is outperforming its "Magnificent Seven" peers in a weak year so far for the group. NVDA 1Y mountain Nvidia stock performance over the past year. Results from Salesforce and Snowflake , also due Wednesday, are another key event for the market this week. Investors will be gauging just how disruptive AI has become to the software industry from the companies' guidance, Woods said. "These stocks need a relief rally and watch their recent lows. They need to hold. If these stocks can bounce, the question is, is this relief or is this something that has changed? Irregardless, we need these stocks to com...
Reform’s ‘shadow home secretary’, Zia Yusuf, launches tirade of misery that sounded more hardline and deranged as it went It was only last week that Nigel Farage declared he was no longer a one-man band with the announcement of a handful of key appointments. Though that does not mean his “Mini-Mes” can yet be trusted to be allowed out on their own. Baby steps and all that. Nige would rather die th...
Reform’s ‘shadow home secretary’, Zia Yusuf, launches tirade of misery that sounded more hardline and deranged as it went It was only last week that Nigel Farage declared he was no longer a one-man band with the announcement of a handful of key appointments. Though that does not mean his “Mini-Mes” can yet be trusted to be allowed out on their own. Baby steps and all that. Nige would rather die than let someone else hog all the limelight. It’s not that his team would screw up. That would be just fine. The worry is always that they might do too well. Might reckon they could live without him. Farage needs to watch them all like a hawk. Continue reading...
GeneDx ( WGS ) is up ~3% in Monday trading after reporting Q4 2025 results that beat on both lines and reiterating 2026 revenue guidance. The genetic testing provider sees revenue this year of $540M-$555M. The consensus is $542.99M. GeneDx was helped in the quarter by a 34.3% year-over-year increase in exome and genome test result volume to 27,761. TD Cowen's Dan Brennan, who rates GeneDx a buy wi...
GeneDx ( WGS ) is up ~3% in Monday trading after reporting Q4 2025 results that beat on both lines and reiterating 2026 revenue guidance. The genetic testing provider sees revenue this year of $540M-$555M. The consensus is $542.99M. GeneDx was helped in the quarter by a 34.3% year-over-year increase in exome and genome test result volume to 27,761. TD Cowen's Dan Brennan, who rates GeneDx a buy with a $165 price target (~101% upside based on Feb. 20 close), said that the company's exome and genome volume guidance "looks to set a high bar" at 33%-35% growth. He added where there is "room for upside" in the stock. Canaccord's Kyle Mikson, who has a buy rating and a $170 price target (~170% upside), noted he would be "further encouraged" if testing volume accelerated beyond expectations. More on GeneDx Holdings GeneDx Holdings Corp. (WGS) Q4 2025 Earnings Call Transcript GeneDx Holdings Corp. (WGS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript GeneDx Holdings Corp. (WGS) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow GeneDx outlines $540M–$555M 2026 revenue target as company accelerates market expansion with new sales force GeneDx Holdings Non-GAAP EPS of $0.18 beats by $0.06, revenue of $121M beats by $0.56M